Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.
Investor Symposium
November 2015
MGC Pharmaceuticals
Company Overview
MGC Pharmaceuticals (MGC), is a medical and
cosmetic cannabis company with licenses to grow,
extract and ...
Some wolves, their habitat destroyed and overwhelmed by human
pressures, turn to snorting quack...
4
Selected Pharmacologic Features of Cannabinoids Showing Antiseizure Effects in Preclinical
Models.
Friedman D, Devinsky O....
MGC Pharma- Key Points Of Difference
7
Sources: Credit Suisse – Market Research, ArcView Group,
• Positioned in the rapidl...
Wealth of industrial cannabis
Sativa (Hemp) managing and
extraction experience, he
shares Mr. Segev’s vision of
building a...
9
Business Model
10
Multiple revenue
streams –
from CBD off-take
agreements and cosmetic
and OTC medical
products sales.
Opp...
11
Medical Cannabis could be legally available in
Australia as early as 2016
12
MGC Australian Strategy
MGC to be first in line to exploit scalable commercial opportunities in Australia for
CBD based ex...
Global Market Opportunity – Medical Cannabis
14
• Cannabinoids are legal in 23 U.S states
and the medical cannabis market ...
15
Capital Structure
16
1. 100,000,000 Performance Shares upon MGC securing an off-take agreement to sell commercial quantiti...
Cannabidiol (CBD) – Global Potential
Scientific and clinical studies indicate that CBD could be effective in easing sympto...
18
CBD- Treatment of Epilepsy
-Despite over 20 different anti-seizure
drugs available, 30% of patients with
epilepsy still ex...
Clinical Trials, Case Series, and Case Reports on Cannabinoids in the Treatment of Epilepsy.
Friedman D, Devinsky O. N Eng...
CBD- Treatment of Chronic Pain
-7 % of Australians suffer some form of chronic
pain
-There are increasing issues with the ...
CBD- Treatment of Cancer
3 Areas of Potential Benefit
1) Chemotherapy induced
nausea
2) Cancer pain
3) Cancer growth & spr...
CBD- Treatment of MS and Alzheimers
3 Areas of Potential Benefit
1) Spasticity
2) Neuropathic pain
3) Central Nervous Syst...
25
CONCLUSIONS
1)MULTIPLE THERAPUETIC BENEFITS
FOR MEDICAL CANNABIS IN THE FORM
OF CBD
2)AN EXTENSIVE RANGE OF SKIN CARE,
COS...
Disclaimer
29
This presentation has been prepared by Erin Resources Limited to be renamed MGC Pharmaceuticals Ltd (“Compan...
Contact Information
30
Media Enquiries
Asher Moses
Director
Media and Capital Partners
+61 438 008 616
Asher.moses@mcpartn...
Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals
Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals
Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals
Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals
Prochain SlideShare
Chargement dans…5
×

Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals

579 vues

Publié le

MGC Pharmaceuticals/Erin Resources - Symposium Investor Roadshow November 2015

  • Holistic clear skin Secrets, Eliminate blemishes in weeks acne cure e-book reveals all ♥♥♥ https://bit.ly/2xJfKi2
       Répondre 
    Voulez-vous vraiment ?  Oui  Non
    Votre message apparaîtra ici

Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals

  1. 1. Investor Symposium November 2015 MGC Pharmaceuticals
  2. 2. Company Overview MGC Pharmaceuticals (MGC), is a medical and cosmetic cannabis company with licenses to grow, extract and sell Cannabis Sativa in Slovenia, inside the EU. MGC holds unique genetics consisting of an exclusive strain of “Cannabis Sativa” which comprises of very low Tetrahydrocannabinol (THC) at below 0.3% and a very high Cannabidiol (CBD) content of above 10%. MGC is currently developing its own product range of cosmetic and over-the-counter (OTC) medical products in partnership with its JV partner, Dr. M. Burstein. MGC Pharmaceuticals Capitalising on “Israeli Medical Cannabis IP” – world leaders in the production and delivery of medical cannabis products 2 $2.7 million initial capital raising completed
  3. 3. Some wolves, their habitat destroyed and overwhelmed by human pressures, turn to snorting quack...
  4. 4. 4
  5. 5. Selected Pharmacologic Features of Cannabinoids Showing Antiseizure Effects in Preclinical Models. Friedman D, Devinsky O. N Engl J Med 2015;373:1048-1058
  6. 6. MGC Pharma- Key Points Of Difference 7 Sources: Credit Suisse – Market Research, ArcView Group, • Positioned in the rapidly growing medical cannabis market (worth US$2.7bn globally) and cosmetic market (estimated at US$270 b globally in 2014) • Focused strategy to enter the Australian market following the favourable regulatory shift by the Federal Government • Unique genetics from exclusive strain of Cannabis Sativa comprising very low THC levels (<0.32) and high CBD levels (>10%) - yielding higher amounts of CBD by 4x against existing hemp crops • Fully Licensed Operation established in Slovenia to Grow, Extract and Import/Export into EU markets • Highly experienced team with commercial success in the medical cannabis industry in Israel - a world leader in the industry • Multiple revenue streams, with significant uplift from full production capacity to be realized in 2017 • $60m off take agreement for MGC’s initial CBD production starting mid 2016 • MGC cosmetic and OTC medical products – first sales and revenues end 2015
  7. 7. Wealth of industrial cannabis Sativa (Hemp) managing and extraction experience, he shares Mr. Segev’s vision of building a large scale European extraction facility and has the necessary skills to establish and run a successful growing operation and extraction facility. He has extensive commercial business contacts in the European industry. Previously CEO of Israel’s second largest licensed Medical Cannabis company, Cann Pharmaceuticals. Led the company to fully commercialize from startup position . Founded MGC Pharmaceuticals to expand into the huge European market for cannabinoids in the cosmetic industry. MC Industry Leaders- Expertise and Experience 8 Nativ Segev Co-Founder and Managing Director Roby Zomer Co-Founder, President & CTO A prominent practising cardiologist and host of weekly radio 2UE program: Healthy Living. He has his own medical practice and specialises in all aspects of echocardiography. Other area of expertise is in the field of preventative cardiology. He has published seven books on preventative health and regularly lectures both nationally and internationally. Dr Ross Walker Non-Executive Director and Head of Advisory Board Joins upon completion of transaction
  8. 8. 9
  9. 9. Business Model 10 Multiple revenue streams – from CBD off-take agreements and cosmetic and OTC medical products sales. Opportunity to leverage growing and extraction expertise in the Australian Market. MGC has a business model which closes the supply chain –demand exists for the end products and MGC is now working towards establishing the supply of the raw material. • Development of Cannabis Strains in Slovenian Laboratory. • Plantation and harvesting of crops in outdoor facility in Slovenia. Cultivation • Crops to be processed on site at Slovenian facility and CBD extracted • Targeting 60% purity CBD resin • MGC has the capability to process other crops on site Extraction • Sell CBD Extract into: • Wholesale markets – other off-takes in pipeline • Off-take with Natura JV to utilise in cosmetic products. Distribution & Sales
  10. 10. 11 Medical Cannabis could be legally available in Australia as early as 2016
  11. 11. 12
  12. 12. MGC Australian Strategy MGC to be first in line to exploit scalable commercial opportunities in Australia for CBD based expertise and products 13 Appointment of Dr Ross Walker as Non-Executive Director and Head of Strategic Advisory Board. Collaboration with University of Sydney Business School on research and commercial opportunities in Australia. Leverage Dr Ross Walker’s significant contacts in Australia and potential for access to distribution channels for MGC’s CBD products. Take advantage of tax incentives from new Federal Government innovation and research push. CompleteNextSteps
  13. 13. Global Market Opportunity – Medical Cannabis 14 • Cannabinoids are legal in 23 U.S states and the medical cannabis market is estimated to be worth USD$2.7 billion globally in 2014 and US$10 billion by 2019 • In Canada the market for medical cannabis is expected to grow significantly, from $144m in 2014 • Common diseases for which Cannabinoids have shown high levels of efficacy have combined sales of +US$300 million to date Sources: ArcView Group, The HIA, Statista
  14. 14. 15
  15. 15. Capital Structure 16 1. 100,000,000 Performance Shares upon MGC securing an off-take agreement to sell commercial quantities of CBD resin that contains a minimum purity of 50%, and achieving first revenues of at least 1m Euro within three years, as detailed in ASX announcement dated 18 May 2015. Note- On completion of acquisition, MGC vendor securities will be escrowed pursuant to Ch 1&2 of the ASX Listing Rules Ordinary Shares Performanc e Shares Unlisted Options Cash Current issued capital 507,586,552 Nil 53,500,000 $2.0m Shares to be issued to consultants and prospectus shares 3,846,700 Nil Nil Nil Underwriting Options to be issued Nil Nil 20,000,000 Nil MGC vendor consideration securities 200,000,000 100,000,0001 Nil Nil Total 711,433,252 100,000,0001 73,500,000 ~$2.0m
  16. 16. Cannabidiol (CBD) – Global Potential Scientific and clinical studies indicate that CBD could be effective in easing symptoms of a wide range of difficult-to-control conditions, including: 17 Nausea Inflammatory Disorders Anxiety and Depression Tumors and Cancerous Cells1 Diabetes Rheumatoid arthritis Epilepsy Schizophrenia Chronic Pain 2 Multiple Sclerosis Skin Conditions: Psoriasis and Acne 1. CBD has demonstrated neuro-protective effects, and its anti-cancer potential is currently being explored at several academic research centers in the U.S. and other countries. 2. Impacts pathways in the body, which control pain and support the immune system, thereby delivering significant medicinal benefits in the treatment of chronic pain
  17. 17. 18
  18. 18. CBD- Treatment of Epilepsy -Despite over 20 different anti-seizure drugs available, 30% of patients with epilepsy still experience seizures -A recent study of 137 patients with severe, refractory epilepsy on maximal standard anti-convulsant therapy, given a purified CBD extract, had a 54% reduction in seizure frequency 19
  19. 19. Clinical Trials, Case Series, and Case Reports on Cannabinoids in the Treatment of Epilepsy. Friedman D, Devinsky O. N Engl J Med 2015;373:1048- 1058
  20. 20. CBD- Treatment of Chronic Pain -7 % of Australians suffer some form of chronic pain -There are increasing issues with the over- prescription of narcotic analgesics & significant side effects of non steroidal anti-inflammatory drugs -A number of studies are showing a significant reduction in pain & improvements in sleep parameters in a variety of CBD based products 21
  21. 21. CBD- Treatment of Cancer 3 Areas of Potential Benefit 1) Chemotherapy induced nausea 2) Cancer pain 3) Cancer growth & spread 22
  22. 22. CBD- Treatment of MS and Alzheimers 3 Areas of Potential Benefit 1) Spasticity 2) Neuropathic pain 3) Central Nervous System inflammation 24
  23. 23. 25
  24. 24. CONCLUSIONS 1)MULTIPLE THERAPUETIC BENEFITS FOR MEDICAL CANNABIS IN THE FORM OF CBD 2)AN EXTENSIVE RANGE OF SKIN CARE, COSMETIC & OTHER OTC PRODUCTS 3)EXCELLENT INVESTMENT OPPRTUNITIES
  25. 25. Disclaimer 29 This presentation has been prepared by Erin Resources Limited to be renamed MGC Pharmaceuticals Ltd (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Future matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.
  26. 26. Contact Information 30 Media Enquiries Asher Moses Director Media and Capital Partners +61 438 008 616 Asher.moses@mcpartners.com.au ERIN soon to be MGC Pharmaceuticals Brett Mitchell Executive Chairman +61 8 9389 2000 brett@mgcpharma.com.au

×